

Schedule 13G

Item 1(a). Name of Issuer:

West Pharmaceutical Services

Item 1(b). Address of Issuer's Principal Executive Offices:

101 Gordon Drive
P.O. Box 645
Lionville, PA 19341-0645

Item 2(a). Name of Person Filing:

Lazard Freres & Co. LLC

Item 2(b). Address of Principal Business Office or, if None, Residence:

30 Rockefeller Plaza
New York, New York 10020

Item 2(c). Citizenship:

New York Limited Liability Company

Item 2(d). Title of Class of Securities:

Common Stock

Item 2(e). CUSIP Number: 955306105

Item 3. If this statement is filed pursuant to Rules 13d-1(b), or 13d-2(b), check whether the person filing is a:

- (a) Broker or Dealer Registered Under Section 15 of the Act
- (e) Investment Adviser registered under section 203 of the Investment Advisers Act of 1940

Item 4. Ownership.

- (a) Amount beneficially owned: 1,138,904
- (b) percent of class: 7.63%
- (c) Number of shares as to which such person has:

(i) Sole power to vote or to direct the vote: 899,596

(ii) Shared power to vote or to direct the vote: None

(iii) Sole power to dispose or to direct the disposition of:
1,138,904

(iv) Shared power to dispose or to direct the disposition of:
None

Item 5. Ownership of Five Percent or Less of a Class.

Not applicable

Item 6. Ownership of More than Five Percent on Behalf of Another Person.

Clients of the Reporting Person have the right to receive dividends and proceeds of sale of the securities reported on this Schedule. To the knowledge of the Reporting Person, no such person has an interest relating to more than five percent of the class of such securities.

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company.

Not applicable

Item 8. Identification and Classification of Members of the Group.

Not applicable

Item 9. Notice of Dissolution of Group.

Not applicable

Item 10. Certification.

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired in the ordinary course of business and were not acquired for the purpose of and do not have the effect of changing or influencing the control of the issuer of such securities and were not acquired in connection with or as a participant in any transaction having such purposes or effect.

SIGNATURE

After reasonable inquiry and to the best knowledge and belief of the undersigned, the undersigned certifies that the information set forth in this Statement is true, complete and correct.

Date: February 3, 2000

/s/ Sr. Donald E. Klein

Sr. Donald E. Klein
Vice President